> ## Content Index > Fetch the complete content index at: https://www.moatmarginresearch.com/llms.txt > Use this file to discover other available public pages before exploring further. # The Moat That Only Works Overseas: Inside UFlex's Pricing Gap - URL: https://www.moatmarginresearch.com/uflex-the-moat-that-only-works-overseas/ - Published: 2026-08-22T03:29:56.000Z - Updated: 2026-09-05T15:38:29.000Z - Description: The same packaging product earns ~2.5x the price overseas versus India. The moat is manufacturing geography, not brand. - Author: A K Karthikeyan - Tags: Moat Insights, Pricing Power, Chemicals **Ask UFlex's CFO where the company makes its money, and the answer isn't a product or a customer segment — it's a passport.** The same flexible packaging that Indian customers won't pay a premium for commands roughly 2.5x the realization once it ships from Egypt, Nigeria, Mexico or Europe. That's not a branding story or a switching-cost story. It's a company that has built manufacturing capacity in enough countries to sell the identical product twice — once at a domestic price, once at a supply-security premium — and its own Q1 FY27 filed transcript says so in plain language. ## The gap, stated directly Asked about margin composition across geographies, the CFO didn't dodge: > "See, our 60% to 65% business is coming from overseas now. When we set up these facilities which are very good and operating margins are much more overseas as compared to Indian business, because in India, the passing of pricing to our customers is slightly difficult, whereas prices can be passed on much easily to our overseas customers, so that is one." > — [UFlex Q1 FY27 filed transcript, 17-Aug-2026, p.20](https://www.bseindia.com/xml-data/corpfiling/AttachLive/57daaf4f-837b-4b63-8429-ca440b4ccca8.pdf) The company isn't claiming a global brand or a patented process here. It is naming a structural fact: the same product, sold out of a different country, clears at a different price — and Indian customers are simply less willing payers than everyone else UFlex sells to. ## Why overseas customers pay it The mechanism only becomes a moat if there's a reason the premium sticks, and the transcript gives one: customers overseas are paying for supply continuity, not for UFlex specifically. During a period the company describes as regional import disruption, its multi-country footprint let it keep serving customers when a single-country competitor couldn't: > "60% to 65% growth will come from overseas markets. Rest will come from Indian market. But India, the volume will be much higher. Prices can be a little softer here." > — [Filed transcript, p.20](https://www.bseindia.com/xml-data/corpfiling/AttachLive/57daaf4f-837b-4b63-8429-ca440b4ccca8.pdf) Five plants across Egypt, Nigeria, Mexico, Europe and India is not a moat any single-country converter can replicate quickly — building it requires years and real capital, and it's the reason customers facing supply disruption pay UFlex a premium rather than sourcing from whoever's cheapest that quarter. Scale-across-geography, not scale-in-one-place, is the edge. ## The domestic side: where the same mechanism runs in reverse The transcript is equally direct about where this doesn't work — the Aseptic Packaging business, facing duty-free competition under an existing trade treaty: > "What has happened in Aseptic, we are getting a lot of duty-free imports from Indonesia, where India has signed a treaty where duty-free imports keep on coming... We are hopeful that even despite this dumping by Indonesia, the volumes requirement in India and other markets will be much higher." > — [Filed transcript, p.13](https://www.bseindia.com/xml-data/corpfiling/AttachLive/57daaf4f-837b-4b63-8429-ca440b4ccca8.pdf) This is the geography mechanism working against UFlex instead of for it: India is the one market where a competitor gets a structural cost advantage (a duty exemption), and UFlex's response is to shift mix rather than fight on price: > "This quarter, of course, our volumes have not grown so much. But value-wise, we have grown. Whatever value addition price we're getting is because now we are moving from normal films to value-added products, which can give us a better realization." > — [Filed transcript, p.13](https://www.bseindia.com/xml-data/corpfiling/AttachLive/57daaf4f-837b-4b63-8429-ca440b4ccca8.pdf) ## The numbers behind the story Consolidated revenue grew 38% YoY to ₹53,972 mn, with EBITDA up 92% YoY to ₹9,198 mn (17% margin) and PAT jumping to ₹4,233 mn from ₹580 mn a year earlier. Management is guiding to 35% YoY top-line and EBITDA growth for FY27, funded partly by ₹4,782 mn of Q1 capex across four projects, including a further ₹1,236 mn into the Egypt Aseptic facility — the company is actively investing in more of the geography that earns the premium. ## The sceptic's reading Two honest limits, stated in the same call. First, overall packaging volumes actually *fell* 8.4% YoY to 37,285 metric tons — the growth story here is a mix shift toward higher-value, higher-margin products and geographies, not rising demand across the board: > "Overall Packaging volumes slipped 8.4% year-on-year to 37,285 metric tons, primarily due to strategic shift towards high-margin products in India... and softness in Aseptic Packaging due to duty-free import at aggressive prices in Indian market." > — [Filed transcript, p.4](https://www.bseindia.com/xml-data/corpfiling/AttachLive/57daaf4f-837b-4b63-8429-ca440b4ccca8.pdf) Second, the pricing gain being cited is explicitly a pass-through, not new pricing power created this quarter — management is careful to frame it as recovery, not expansion: > "Whatever gain you are seeing in our volume as well as in our prices, they are the prices which have been passed on to the customers." > — [Filed transcript, p.19](https://www.bseindia.com/xml-data/corpfiling/AttachLive/57daaf4f-837b-4b63-8429-ca440b4ccca8.pdf) And the balance sheet funding this geographic footprint isn't yet where management wants it — leverage is still elevated, with a stated target of bringing it "below 3x by FY28," meaning the capital structure hasn't fully caught up to the strategy. ## What would confirm the story This is genuinely new territory for a moat framework built mostly around domestic pricing power and distribution — UFlex's edge, if real, is a manufacturing-footprint arbitrage that most Indian-listed peers simply don't have the capital or history to replicate. What would confirm it: whether the 60-65%-overseas mix holds or grows as India's own duty treaties evolve, whether the \~2.5x realization gap compresses as competitors build overseas capacity of their own, and whether leverage actually falls toward the 3x target on schedule. UFlex isn't in our scored universe yet — this is observation, not a MoatSCORE claim. --- > Educational research, not investment advice. All quotes are verbatim from the company's filed transcript, extracted and verified against the source PDF linked above. No buy/sell recommendations, no price targets. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.